Showing 1841-1850 of 5771 results for "".
- Ocular Therapeutix Announces First Patient Dosed in US-Based Phase 1 Trial of OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-us-based-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2479421/Ocular Therapeutix announced that it has dosed the first patient in the United States phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (AMD). “We are very excited to have recently begu
- Aurion Biotech Announces IOTA Cell Therapy Trialhttps://modernod.com/news/aurion-biotech-announces-iota-cell-therapy-trial/2479415/Aurion Biotech announced preliminary findings from its IOTA trial, conducted in November 2020 and in May of this year, at the Clínica Quesada in San Salvador, El Salvador. In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell th
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- BVI Announces Collaboration With BeyeOnics Visionhttps://modernod.com/news/bvi-announces-collaboration-with-beyeonics-vision/2479411/BVI announces a collaboration with Israel-based BeyeOnics Vision, a maker of in head-mounted display, digital data, and imaging processing. BeyeOnics Vision has been developing BeyeOnics 1, which the company describes as the first and only ophthalmic digital imaging system replacing the op
- Sight Sciences Announces Multiple Presentations at ASCRShttps://modernod.com/news/sight-sciences-announces-multiple-presentations-at-ascrs/2479400/Sight Sciences announced that data from multiple retrospective and prospective clinical studies of the OMNI Surgical System and TearCare System will be presented at the 2021 ASCRS Annual Meeting. The in-person conference will take place July 23-27 in Las Vegas. A total of five
- Ocuphire Announces Publication Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Diseasehttps://modernod.com/news/ocuphire-announces-publication-featuring-its-oral-ref-1-inhibitor-apx3330-in-phase-2-trial-for-the-treatment-of-retinal-disease/2479396/Ocuphire Pharma announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled “APE1/Ref-1 as a Novel Target for Retinal Disease.” The Journal of Cellula
- Surface Ophthalmics Announces $25 Million Private Round of Fundraisinghttps://modernod.com/news/surface-ophthalmics-announces-25-million-private-round-of-fundraising/2479393/Surface Ophthalmics announced it has secured gross proceeds of approximately $25 million in a private placement of preferred stock, at a purchase price of $4.50 per share. Investors in this round of financing included both new and existing investors made up of institutional, healthcare-focused, a
- Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-Cleared AI Technology for Detection of Diabetic Retinopathyhttps://modernod.com/news/eyenuk-announces-6-2-million-financing-to-accelerate-adoption-of-fda-cleared-ai-technology-for-detection-of-diabetic-retinopathy/2479388/Eyenuk announced that it has completed a financing round of $6.2 million to accelerate commercialization of the EyeArt AI System, which received FDA clearance in 2020 and is being reimbursed by Medicare and other payo
- Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with RPhttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-phase-2b-trial-of-optogenetic-gene-monotherapy-to-restore-vision-in-patients-with-rp/2479381/Nanoscope Therapeutics announced that the first patient had been dosed in its phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigme
- Prevent Blindness Holds 10th Annual Focus on Eye Health National Summithttps://modernod.com/news/prevent-blindness-holds-10th-annual-focus-on-eye-health-national-summit/2479376/Prevent Blindness held the 10th annual